

Exact Sciences, Mayo advance biomarker panel for liver cancer

June 6, 2018 | News

The results were presented at Digestive Disease Week in Washington, DC.



Singapore- Exact Sciences and Mayo Clinic researchers announce progress in developing a panel of blood-based DNA biomarkers to detect hepatocellular carcinoma (HCC), the most common type of liver cancer. The results were presented at Digestive Disease Week in Washington, DC.

To date, the panel has demonstrated 95% sensitivity in detecting HCC across all stages with a specificity (correctly identifying true negatives) of 93%. Sensitivity among patients with curable-stage disease was 91%.

Mayo Clinic's John Kisiel, M.D., says, "Now we must confirm the accuracy of the biomarkers we've studied for the detection of HCC. We are seeking to apply this DNA assay technology to all cancers, and these findings are an important step toward that goal."